23558-62-5 Usage
Description
(2R,3R,4S,5R)-2-(6-(benzylamino)-2-chloro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol is a complex organic molecule characterized by a purine ring with a benzylamino group and a chlorine substituent, as well as a tetrahydrofuran ring with a hydroxymethyl group. The molecule's stereochemistry is indicated by the R and S designations, which describe the spatial arrangement of its atoms. (2R,3R,4S,5R)-2-(6-(benzylamino)-2-chloro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol may exhibit potential biological activity due to its purine structure, and the hydroxymethyl group could participate in chemical reactivity or binding to other molecules. The benzylamino group may also provide specific properties or interactions with biological systems.
Uses
Used in Pharmaceutical Industry:
(2R,3R,4S,5R)-2-(6-(benzylamino)-2-chloro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol is used as a potential pharmaceutical candidate for [application reason]. Its purine structure may offer biological activity, and the hydroxymethyl group could be involved in binding to target molecules or enhancing solubility. The benzylamino group may also contribute to specific interactions with biological systems, making it a promising compound for drug development.
Used in Chemical Research:
In the field of chemical research, (2R,3R,4S,5R)-2-(6-(benzylamino)-2-chloro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol serves as a subject for studying the effects of stereochemistry on molecular properties and reactivity. Its complex structure allows for investigations into the role of functional groups and their influence on chemical behavior, which can be valuable for the development of new synthetic methods or the understanding of molecular recognition processes.
Check Digit Verification of cas no
The CAS Registry Mumber 23558-62-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,5,5 and 8 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 23558-62:
(7*2)+(6*3)+(5*5)+(4*5)+(3*8)+(2*6)+(1*2)=115
115 % 10 = 5
So 23558-62-5 is a valid CAS Registry Number.
23558-62-5Relevant articles and documents
Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors
Sharif, Ehesan U.,Kalisiak, Jaroslaw,Lawson, Kenneth V.,Miles, Dillon H.,Newcomb, Eric,Lindsey, Erick A.,Rosen, Brandon R.,Debien, Laurent P. P.,Chen, Ada,Zhao, Xiaoning,Young, Stephen W.,Walker, Nigel P.,Str?ter, Norbert,Scaletti, Emma R.,Jin, Lixia,Xu, Guifen,Leleti, Manmohan R.,Powers, Jay P.
, p. 845 - 860 (2021/02/05)
Solid tumors are often associated with high levels of extracellular ATP. Ectonucleotidases catalyze the sequential hydrolysis of ATP to adenosine, which potently suppresses T-cell and NK-cell functions via the adenosine receptors (A2a and A2b). The ectonucleotidase CD73 catalyzes the conversion of AMP to adenosine. Thus, increased CD73 enzymatic activity in the tumor microenvironment is a potential mechanism for tumor immune evasion and has been associated with poor prognosis in the clinic. CD73 inhibition is anticipated to restore immune function by skirting this major mechanism of adenosine generation. We have developed a series of potent and selective methylenephosphonic acid CD73 inhibitors via a structure-based design. Key binding interactions of the known inhibitor adenosine-5′-(α,β-methylene)diphosphate (AMPCP) with hCD73 provided the foundation for our early designs. The structure-activity relationship study guided by this structure-based design led to the discovery of 4a, which exhibits excellent potency against CD73, exquisite selectivity against related ectonucleotidases, and a favorable pharmacokinetic profile.
CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF
-
Paragraph 0149, (2020/04/09)
CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof.
